Abstract Patients with L-2-hydroxyglutaric aciduria are at risk for developing cerebral neoplasms, particularly gliomas, as one of the optical isomers of the known oncometabolite, 2-hydroxyglutarate is produced in L-2-hydroxyglutaric aciduria. To illustrate the concept of sustained oncogenic potential in permanent exposure to L-2-hydroxyglutarate in brain tissue, we present the medical history of a patient with L-2-hydroxyglutaric aciduria who underwent surgery to remove a right temporal anaplastic astrocytoma and developed an anatomically distinct, but histopathologically similar, tumor in the left frontal region 40 months later. This is the first reported case of successive distinct gliomas in a patient with L-2-hydroxyglutaric aciduria. While this implies a significant, cumulative lifetime risk for cerebral neoplasms in patients with this rare organic aciduria, it also allows further insight into a unique mechanism of tumorigenesis in the brain.
Introduction
L-2-hydroxyglutaric aciduria (OMIM: 236792) is a rare inborn error of metabolism with autosomal recessive inheritance. Only 300 cases have been reported since the initial description in 1980 (Duran et al 1980) and 1992 (Barth et al 1992) . The condition is caused by mutation of the L2HGDH g e n e , ( To p c u e t a l 2 0 0 4 ) w h i c h e n c o d e s L -2 -hydroxydehydrogenase, a FAD-linked mitochondrial membrane enzyme (Rzem et al 2004) that normally catalyzes the conversion of L-2-hydroxyglutarate to alpha-ketoglutarate. Mutation leads to deficient enzyme production and, thus, to excess L-2-hydroxyglutarate accumulation in affected cells and body fluids. The L2HGDH gene is strongly expressed in t h e C N S ; t h u s , t h e c o m b i n a t i o n o f L -2 -hydroxydehydrogenase deficiency and the resultant L-2-hydroxyglutaric aciduria is often referred to as a "neurometabolic disorder". This has a protracted clinical course characterized by cognitive and motor delay, epilepsy, and cerebellar and extrapyramidal signs, but unlike most other organic acidurias, without episodes of systemic metabolic decompensation. The tissue specificity and relatively mild symptomatology often allow patients to live into adulthood without systemic manifestations.
L-2-hydroxyglutaric aciduria demonstrates pathognomonic findings on MRI. These include white and gray matter abnormalities (D'Incerti et al 1998; Steenweg et al 2009) that are typically present by childhood and progress very slowly (Topcu et al 2005; Steenweg et al 2009) . For this reason and because the metabolic disease is untreatable and not complicated by episodes of metabolic decompensation, regular imaging for patients with L-2-hydroxyglutaric aciduria has not been advocated.
Patients with L-2-hydroxyglutaric aciduria have an increased risk for the development of cerebral neoplasms (Moroni et al 2004) . However, given that a prospective, longitudinal follow-up study has not been done, the suggested 5 % to 40 % risk of developing a cerebral neoplasm (Patay et al 2012) may be an underestimate of the actual cumulative lifetime risk. Because exposure to L-2-hydroxyglutarate is continuous in patients with L-2-hydroxyglutaric aciduria, it is conceivable that they remain at risk for tumorigenesis throughout their entire lives. Here, we report the case of a patient with L-2-hydroxyglutaric aciduria who developed two successive high-grade diffuse gliomas at different cerebral locations three years apart. These findings substantiate the possibility of multiple, sequentially developing CNS neoplasms; hence provide a rationale for a surveillance strategy in patients with L-2-hydroxyglutaric aciduria.
Case report
A man aged 22 years with a history of L-2-hydroxyglutaric aciduria had a brain MRI study as part of the investigation of his headaches. A small, right mesial temporal, intra-axial mass was i dentified and was subsequently resected. Histopathologic evaluation indicated a diagnosis of anaplastic astrocytoma (WHO grade III). Subsequently, he received local proton beam radiation therapy to a total dose of 54 CGE. The patient had surveillance brain MRI studies at regular intervals after completion of radiation therapy. Forty months later new MRI abnormalities were suggested in the left frontal lobe, without any recurrence at the primary tumor site or signs to suggest transcallosal spread (Fig. 1) .
Because the MRI abnormalities were subtle and difficult to differentiate from the extensive leukodystrophy-like changes throughout both cerebral hemispheres, an 11 C-methionine PET CT study was performed. Images were obtained for 15 minutes after administration of 20 mCi (740 MBq) of 11 C-methionine. Co-registration with previously acquired MR images showed increased tracer uptake in the left frontal parasagittal region corresponding to the area of MRI abnormality (Fig. 2) .
At this time, the patient was clinically asymptomatic, but in view of the history of astrocytoma, this lesion was surgically resected. Histopathologic findings again indicated a diagnosis of anaplastic astrocytoma (WHO grade III). Interphase fluorescence in situ hybridization of the second tumor demonstrated amplification of the epidermal growth factor receptor (EGFR) gene in 33 % of cells (Fig. 3) .
A retrospective evaluation of tissue from the patient's first tumor also revealed EGFR amplification. The patient received proton beam irradiation (54 CGE) to the site of the second brain tumor. Since that time a year ago, the patient's clinical course has been unremarkable. Of note, an older sibling of the patient also had L-2-hydroxyglutaric aciduria and an embryonal rhabdomyosarcoma of the bladder.
TCGA data analysis
EGFR amplification was detected in tissue from both tumors. Such amplification is unusual in the setting of IDH1-mutant tumors. To investigate this phenomenon further, we evaluated mutation and copy number data from a cohort of 500 adult infiltrating gliomas (WHO grade II to IV) with mutation and copy number data downloaded from The Cancer Genome Atlas (TCGA) cBIO portal (http://www.cbioportal.org/) (Cerami et al 2012) .
IDH1 was mutated in 112 out of 132 WHO grade II (85 %), 86 out of 133 grade III (65 %), 12 out of 235 grade IV (5 %) and 210 out of all 500 tumors (42 %). EGFR was mutated or amplified in 1 out of 132 grade II (0.76 %), 26 out of 133 grade III (20 %), 143 out of 235 grade IV (61 %), and 170 out of all 500 tumors (34 %). Only a single grade II tumor had a mutation in EGFR. Of 26 grade III tumors, 20 had EGFR amplification, and 14 had EGFR mutations (a subset of eight showed both alterations). Of 143 grade IV tumors, 132 had EGFR amplification, and 67 had EGFR mutations (a subset of 56 showed both alterations).
Of 112 IDH1-mutant grade II tumors, none showed EGFR amplification or mutation. Of the 86 IDH1-mutant grade III tumors, two showed EGFR amplification, and one had a mutation in EGFR, yielding a rate of 2.26 % for the coincidence of IDH1 and EGFR alterations. Interestingly, one of the IDH1-wildtype grade III tumors had a combination of L2HGDH mutation, EGFR mutation, and EGFR amplification. Of 12 IDH1-mutant grade IV tumors, none showed EGFR amplification, and only one had a mutation in EGFR, yielding a rate of 0.43 % for the co-incidence of IDH1 and EGFR alterations.
EGFR alterations and IDH1 mutations were mutually exclusive for grade III and grade IV, as well as for all tumors (Fisher's exact test: P<0.001 for grade III, grade IV and all tumors). EGFR alteration was more frequently observed in IDH1 wild-type patients than in those with IDH1 mutations for grade III, grade IV and all tumors (odds ratio: 26.51; 95 % exact confidence interval: 6.93-145.05 for grade III tumors; odds ratio: 19.28; 95 % exact confidence interval: 2.69-835.70 for grade IV tumors; odds ratio: 68.94; 95 % exact confidence interval: 25.27-260.45 for all tumors).
Discussion
In view of the current understanding of tumorigenesis in L-2-hydroxyglutaric aciduria, our case suggests that patients with this disease may have a significant lifetime risk for brain tumors and, therefore, may potentially benefit from surveillance imaging. However, the imaging modality used must be adequately sensitive. The presence of prominent and extensive white matter abnormalities relating to the metabolic disease renders the MRI evaluation of brain parenchyma and the early detection of infiltrative brain tumors challenging, as is well demonstrated in our case. Therefore, other imaging modalities, such as nuclear medicine techniques, using wellestablished (e.g., 18 fluorodeoxyglucose) or investigational (e.g.,
11
C-methionine) metabolic tumor tracers, may be less prone to interference from the leukodystrophy-type changes and more sensitive as a first-line surveillance technique.
We opted to use 11 C-methionine PET in this case, because of our past experience with its enhanced sensitivity in various neoplastic processes of the brain, particularly in cases where MRI was inconclusive. In our case, the results of the 11 Cmethionine PET study provided the necessary degree of The findings in the left frontal lobe on the second study are subtle, but comparison with the findings of the earlier study reveals interval changes with increasing T2 signal involving the left lesser forceps and mild expansion of the genu of the corpus callosum, which suggests an infiltrative space-occupying process. This lesion was not associated with signal enhancement on post-contrast, T1-weighted images (not shown). All images from both studies (a-f) show extensive white matter abnormalities within cerebral hemispheres exhibiting a centripetal gradient, with deeper structures, such as corpus callosum, being relatively spared in conjunction with signal changes within caudate nuclei and putamina C-methionine PET in this particular case, we recognize that the interpretation of these studies may be problematic, because the nuclear medicine imaging correlates of L-2-hydroxyglutaric aciduria are unknown. However, it is conceivable that the myelinoclastic lesions are characterized by decreased or nearly normal metabolic activity, facilitating the identification of a hypermetabolic neoplastic process against this background.
Mutations of the isocitrate dehydrogenase genes IDH1 and IDH2 encoding the cytosolic enzyme isocitrate dehydrogenase-1 and the mitochondrial isoenzyme isocitrate dehydrogenase-2, respectively, drive tumorigenesis in sporadic infiltrating gliomas, including grade II astrocytomas, grade III astrocytomas (Hartmann et al 2009) , and secondary glioblastoma (Parsons et al 2008; Yan et al 2009) . However, IDH1 mutations and L2HGDH deficiency lead to the accumulation of different potential oncometabolites. In the case of IDH1 mutation, D-2-hydroxyglutarate is produced; whereas, in L-2-hydroxyglutaric aciduria the L stereoisomer accumulates (Dang et al 2009) . Our understanding of the putative mechanism of tumorigenesis in D-2-hydroxyglutaric aciduria has been enhanced by the discovery of the role of residue R132 mutations in IDH1-mutant tumors (Yan et al 2009) . This mutation results in structural changes in the protein, which shifts the active site in the mutant IDH1 enzyme and leads to reduced oxidative decarboxylation of isocitrate and the conversion of alpha-ketoglutarate to D-2-hydroxyglutarate, the enantiomer of the L-2-hydroxyglutarate that is overproduced in patients with L-2-hydroxyglutaric aciduria (Dang et al 2009) .
The mechanisms leading to increased 2-hydroxyglutarate in L-2-hydroxyglutaric aciduria and in IDH-mutated brain tumors are distinct and result in the accumulation of different 2-hydroxyglutarate isomers within the target organ, the brain, but there may be other differences too. Increased levels of D-2-hydroxyglutarate in tumors with sporadic IDH1 or IDH2 mutations may be regional, which however subsequently may spread to more remote areas of the brain as neoplastic cells infiltrate adjacent brain parenchyma. Conversely, in L-2-hydroxyglutaric aciduria, exposure to L-2-hydroxyglutarate involves the entire brain from birth to death; hence, the carcinogenic exposure is diffuse and permanent.
The oncogenic potential of exposure to 2-hydroxyglutarate is now widely accepted. D-2-hydroxyglutarate has been found to inhibit the histone demethylation required for lineagespecific progenitor cells to differentiate (Lu et al 2012) . In vitro studies have also shown that D-2-hydroxyglutarate promotes proliferation of human astrocytes through the stimulation of EGLN gene activity and a consequent reduction of hypoxia-inducible factor (HIF), a transcription factor that regulates cellular response to hypoxia) levels (Koivunen et al 2012) . These data suggest that IDH mutations lead to changes in cellular metabolism, a "hypermethylation" phenotype and an altered ability to respond to hypoxia and oxidative stress (Cohen et al 2013) . The above properties have not been demonstrated for L-2-hydroxyglutarate. It is noteworthy that although brain abnormalities in both types 1 and 2 D-2-hydroxyglutaric aciduria (other, rarer inborn errors of metabolism, OMIM: 609186 and 147650, respectively) are well-documented in the literature, no association with neoplasia in the brain or any other organ has been reported (Kranendijk et al 2012) . Given the existing L-2-hydroxyglutaric aciduria literature, it is conceivable that another effect of excess L-2-hydroxyglutarate on brain tissue might be myelinotoxicity, especially in the developing brain. Although L-2-hydroxyglutarate produces non-specific biochemical effects (e.g., inhibition of creatine kinase activity, induction of oxidative stress), any mechanism for the myelinotoxicity remains uncertain (da Silva et al 2004) (Latini et al 2003) . On MRI, hemispheric white matter is extensively affected, with a centrifugal pattern, but the cerebellum, brain stem, corpus callosum, pyramidal tracts, and deep, periventricular white matter are spared. The explanation for this characteristic pattern of "selective vulnerability" is currently unclear.
An interesting aspect of the tumor specimens from our patient was the unexpected finding of EGFR amplification. While the occurrence of EGFR amplification in both tumors in our patient could potentially suggest that the second tumor is a distant recurrence of the initial tumor, the MRI findings strongly argue against that possibility. Our statistical analysis supports strong mutual exclusivity of EGFR alterations and IDH1 mutations in infiltrative gliomas. It is possible that distinct oncogenic driver mechanisms are utilized for D-2-hydroxyglutarate-induced and L-2-hydroxyglutarate-induced tumorigenesis such that the latter selects for EGFR activation. The finding of an additional case of a grade III astrocytic tumor and EGFR alterations in a L2HGDH-mutant tumor in the TCGA data set further supports this hypothesis. One may speculate that EGFR activation may contribute to the white matter disease in addition to the carcinogenic process, because EGFR activation has also been found to mediate inhibition of axon regeneration by myelin. The yet poorly understood relationship between EGFR and myelin-dependent neuroaxonal repair (Koprivica et al 2005) may merit further evaluation.
